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Summary 1,4,8,11,15,18,22,25-Octadecylphthalocyaninato zinc(II), ZnODPc, incorporated into a Cremophor
emulsion, was assayed for its pharmacokinetic and phototherapeutic properties in Balb/c mice bearing an
intramuscularly transplanted MS-2 fibrosarcoma. The phthalocyanine was injected intravenously (i.v.) in three
doses, i.e. 1.46, 0.73 and 0.37 ttmol kg-' body weight. In all cases, the octadecyl-substituted phthalocyanine
showed an unusually high affinity for serum low-density lipoproteins (LDLs) and a high efficiency and
selectivity of tumour targeting: the maximum accumulation in the tumour occurred at 24 h after injection,
whereas no detectable amount of phthalocyanine was recovered from the muscle, i.e. the peritumoral tissue,
between I h and 1 week after injection. At the same time, low amounts of phthalocyanine were recovered from
skin and then only at short times after injection, with skin photosensitivity rapidly disappearing and the
phthalocyanine present in the serum only. Tumour photosensitisation studies were carried out at 24 h after
administration of 1.46 ,umol kg-' ZnODPc and showed that this phthalocyanine has a very high
phototherapeutic efficiency; this is probably a consequence of the multiple mechanisms by which the
phthalocyanine induces tumour damage, involving both direct modification of malignant cells and impairment
of blood flow, as well as the alteration of a variety of subcellular components, such as mitochondria, the rough
endoplasmic reticulum, the perinuclear membrane and, occasionally, cell nuclei. Tumour necrosis appears to be
the consequence of both random cell death and apoptosis.
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The chemical structure of porphyrinoid derivatives appreci-
ably affects their pharmacokinetic behaviour in tumour-
bearing animals, including their distribution among the
various compartments of cells or tissues (Jori, 1989;
Henderson and Dougherty, 1992); this in turn influences
the efficiency and mechanism by which photoactivated
porphyrinoids induce tumour necrosis in photodynamic
therapy (PDT) (Hamblin and Newman, 1994). Several
factors have been identified as modulators of the photo-
therapeutic activity: thus, hydrophobic dyes exhibit a
particularly high affinity for malignant cells, while more
hydrophilic compounds are preferentially released to the
extracellular matrix, hence they mainly photosensitise
through damage to the vascular system (Henderson and
Bellnier, 1989; Moan and Berg, 1992); in several cases, the
selectivity of tumour targeting can be enhanced by the
association of the photosensitiser with suitable delivery
systems before systemic injection (Jori, 1992; Garbo, 1990);
the presence of electrically charged or bulky peripheral
substituents and/or axial ligands to the centrally coordinated
metal ions minimises the tendency of porphyrinoids to
undergo aggregation which often lowers their photosensitis-
ing efficiency (Jori, 1995); lastly, cationic dyes appear to
develop a very specific interaction with the mitochondria of
neoplastic cells (Dougherty, 1993).
On these bases, it appears important to obtain detailed
information on structure-activity relationships, especially for
those second-generation PDT agents that are being tested at
the clinical level or are approaching clinical trials. For some
years, we have focused our investigations on phthalocyanines,
whose spectral properties and -in vivo biodistribution are
markedly influenced by the nature of the coordinated metal
ion, its axial ligands and the peripheral side groups from the
isoindole moieties (Jori and Reddi, 1991; Spikes, 1986; Soncin
et al., 1995a). In this paper, we report our findings on a novel
highly substituted phthalocyanine, namely 1,4,8,11,15,18,22,
25-octadecylphthalocyaninato Zinc(II) (ZnODPc), which was
shown to possess excellent photophysical properties in vitro
(Cook et al., 1995); moreover, preliminary in vivo investiga-
tions appear to suggest that ZnODPc displays unusual
pharmacokinetic and phototherapeutic features (Cook et al.,
1994) that should be explored further. Our studies were
performed with Balb/c mice bearing an intramuscularly
transplanted MS-2 fibrosarcoma, i.e. an animal model which
has been frequently used in our laboratories (Reddi et al.,
1987; Cuomo et al., 1991; Villanueva et al., 1994) for
experimental PDT studies, so that meaningful comparisons
between ZnODPc and other PDT agents could be made.
Materials and methods
Animals and tumour
Female Balb/c mice, 20-22 g body weight, were purchased
from Charles River (Como, Italy) and housed in standard
cages with free access to tap water and normal dietary food.
The mice were treated according to the guidelines established
by the Italian committee for humane care of experimental
animals. Tumour implantation was performed by intramus-
cular injection of a sterile aqueous suspension (0.2 ml) of 106
cells of MS-2 fibrosarcoma into the right hind leg; the
tumour was originally obtained from the Istituto Nazionale
dei Tumori (Milan, Italy). No spontaneous regression or
remission of the tumour was observed during our investiga-
tions.
Chemicals
The synthesis of 1,4,8,11,15,18,22,25-octakis-decylphthalocya-
ninatozinc (ZnODPc, molecular weight 1700) has been
described elsewhere (Cook et al., 1995). The phthalocyanine
was incorporated into aqueous emulsions of Cremophor EL
(Sigma) (Cook et al., 1994), and its concentration was
determined by diluting a known aliquot of the emulsion
into a known excess of tetrahydrofuran and measuring the
absorbance at 701 nm (c=2.01 x 105 dm3 mol 'cm-). In
general, the ZnODPc concentration in the emulsion was c.
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0.25 mg ml-'. Sodium dodecyl sulphate (SDS) and tetrahy-
drofuran were purchased from Merck and used as received.
All other solvents and chemicals were commercial products of
at least analytical grade.
Pharmacokinetic studies
In a typical experiment, on the seventh day after transplanta-
tion, when the tumour diameter was 0.6-0.8 cm, the mice
were injected into the tail vein with 0.37, 0.73 and 1.46 jumol
of Cremophor-incorporated ZnODPc per kg body weight. At
predetermined times after injection, groups ofthree mice were
sacrificed by prolonged exposure to vapours of diethyl ether:
blood samples (c. 1.0 ml per mouse) were taken intracardia-
cally, centrifuged for 15 min at 3000 r.p.m. in order to
remove the blood cells, and the sera thus collected were
pooled and 10-fold diluted with 2% aqueous SDS. At the
same time, the tumour and selected normal tissues were
rapidly excised, washed with physiological solution and a
weighed amount of tissue (c. 200 mg) was homogenised in
2% aqueous SDS (3 ml) using a Potter vessel; the
homogenate was incubated for 1 h at room temperature
under gentle magnetic stirring, then 1 ml of the suspension
was diluted with tetrahydrofuran (2 ml) and centrifuged at
3000 r.p.m. for 10 min. Both the serum and the tissue
extracts were assayed for the ZnODPc content by reading
the 650 nm-excited phthalocyanine fluorescence emission in
the 670-770 nm spectral interval. The fluorescence intensity
was converted into ZnODPc concentration by interpolation
with a calibration plot (Reddi et al., 1987). Under these
experimental conditions, more than 95% phthalocyanine was
recovered from the tissue specimens.
In parallel experiments, 2 ml of pooled mouse sera
obtained at 24 h after i.v. injection of ZnODPc were
subjected to discontinuous density gradient ultracentrifuga-
tion (Havel et al., 1985), in order to isolate the following
serum protein fractions: very low-density (VLDL), low-
density (LDL), high-density (HDL) lipoproteins, and heavy
proteins (d> 1.2, mainly globulins and albumin). Then,
0.4 ml of the individual fractions were added with 0.4 ml of
4% aqueous SDS, diluted with 1.5 ml oftetrahydrofuran and
the amount of associated ZnODPc was determined by
spectrofluorimetric analysis.
Phototherapeutic studies
Irradiation of the tumour-bearing mice was performed at
24 h after i.v. injection of 1.46 imol kg-' Cremophor-
incorporated ZnODPc by 620-700 nm light isolated from
the emission of a quartz/halogen lamp (Teclas, Lugano,
Switzerland) by means of a band-pass filter. The light source
was operated at 230 mW cm-2 for a total delivered light dose
of 400 J cm-2. The beam was piloted to the irradiation site
by a bundle of optical fibres whose tip (diameter 0.8 cm) was
kept at a distance of 1 cm from the mouse skin. Previous
studies (Soncin et al., 1995b) have shown that under these
irradiation conditions the tumour temperature does not rise
beyond 38°C, so that any hyperthermal effect could be
discounted (Biolo et al., 1994). During irradiation the mice
were anaesthetised by intraperitoneal administration of
ketalar (0.5 ml per 20 g of body weight).
The growth of the fibrosarcoma in the phototreated
animals was compared with that observed for control
unirradiated mice.
At predetermined post-irradiation times, the mice were
sacrificed by prolonged exposure to ether vapours, the
tumour was rapidly excised and fixed with glutaraldehyde
for ultrastructural studies (Milanesi et al., 1990). The
ultrathin sections were analysed by an Hitachi H-600
electron microscope. At least three mice for each post-
irradiation time were examined.
Skin photosensitivity studies
Healthy Balb/c mice that received 1.46 Mmol kg-' ZnODPc
were irradiated in the right hind leg at 3 h, 15 h and 24 h
after i.v. administration of the phthalocyanine. The light
source was operated at a fluence rate of 230 mW cm-2, in the
absence of band-pass filters, so that the incident light
extended from 360-800 nm; the total light dose was
400 J cm-2. The skin reponse to the phototreatment was
assessed at daily intervals for about 1 week after irradiation.
In a different set of experiments, control and phototreated
mice (irradiation at 3 h after injection) were sacrificed at 3 h
after the end of irradiation. The irradiated skin area and an
equivalent sample of unirradiated skin were taken and fixed
for optical microscopy (Milanesi et al., 1991). Observations
were carried out with a Leitz Dialux 22 instrument.
Results
Pharmacokinetic studies
The distribution of ZnODPc among plasma proteins of Balb/
c mice was studied at 24 h after i.v. injection of different
phthalocyanine doses (Table I). This time interval was
selected since the release of hydrophobic substrates from
Cremophor to serum proteins has been shown to be a slow
process (Kongshaug et al., 1992), hence at shorter post-
Table I Distribution of ZnODPc among mouse plasma proteins at
24 h after i.v. administration of the phthalocyanine in a Cremophor
EL emulsion
Injected
dose (Itmol Percentage recovery
kg-') VLDL LDL HDL HP Cremophor
1.46 2.2 69.9 13.2 2.7 12.0
0.73 - 72.9 12.2 1.8 13.1
0.37 45.0 35.8 - 19.2
Protein fractions were separated by density gradient ultracentrifuga-
tion and the amount of associated phthalocyanine was measured by
spectrofluorimetry. HP, heavy proteins.
Table II Recovery (ng of dye per mg of tissue) of ZnODPc from serum and selected tissues of Balb/c mice
bearing an intramuscularly transplanted MS-2 fibrosarcoma
Recovery (ng mg-1)
Tissue J h 3 h 6 h 15 h 24 h I week
Tumour 2.2+0.4 3.0+0.6 4.4+0.3 5.5+0.3 5.5+ 1.1 0.8+0.3
Muscle nd nd nd nd nd nd
Skin nd 0.1 +0.03 0.3+0.1 nd 0.2+0.05 nd
Liver 2.7+0.2 3.6+0.4 8.5+0.2 16.1 +2.6 20.3+2.2 10.4+ 1.1
Spleen 1.3 +0.05 1.9+0.6 2.9+0.2 4.7+0.7 7.2+0.4 4.0+0.02
Kidney 1.7+0.5 1.8+0.6 1.4+0.3 0.4+0.1 0.3+0.02 nd
Lung 1.4+0.3 1.2+0.2 0.9+0.03 0.3+0.1 0.2+0.04 nd
Brain 0.2+0.1 0.1 +0.04 0.2+0.04 nd nd nd
Seruma 38.5+5.4 28.5+3.4 21.1 +0.5 5.0+0.2 1.8+0.4 nd
The mice were injected i.v. with 1.46 imol kg-' ZnODPc solubilised in a Cremophor EL emulsion. apg ml-;
nd, not detected.injection times a substantial aliquot of ZnODPc would still
have been associated with the oil emulsion. Clearly,
essentially all the recovered phthalocyanine is bound to
lipoproteins, as is typical of photosensitising agents that are
administered via lipid-type delivery systems (Kongshaug et
al., 1992). Unexpectedly, however, about 70% of ZnODPc is
recovered from the LDL fraction, in spite of the fact that
LDL represents only a minor component of the lipoprotein
family in mice (Chapman, 1986). In general, the distribution
of lipophilic phthalocyanines and their analogues among
lipoproteins reflects the percentage composition of the
various subclasses, such as VLDL, LDL and HDL, hence
the amount associated with LDL ranges between 25% and
30% (Jori, 1985).
Table II shows the distribution of ZnODPc
(1.46 ymol kg-1) in the tumour and several normal tissues,
as well as in the serum, as a function of the post-injection
time. The pharmacokinetic studies were limited to 1 week,
since at longer times the tumour size became excessive with
severe alterations of the overall metabolism and possible
death of the mice. At all time points studied by us, no
detectable amount of ZnODPc was found in muscle, which
represents the peritumoral tissue in this animal model.
These studies were extended to different doses of ZnODPc
but the recoveries were measured only at a relatively short
post-injection time (3 h) and at 24 h, which corresponds with
the time selected for phototherapeutic experiments (see
below). The data are shown in Table III and represent the
averaged recoveries from five independently analysed mice at
each time point. It is apparent that the maximum
accumulation of ZnODPc in tissues increases with the
injected dose. In particular, for liver, spleen and tumour,
the kinetics ofphthalocyanine uptake is particularly slow and
the intratissular concentration reaches maximum values at
24 h after injection. In no case is any detectable amount of
phthalocyanine found in extracts from the muscle and skin.
Since the rate of photosensitiser clearance from the
organism is an important factor for the design of new
phototherapeutic agents, we also examined the retention of
ZnODPc in selected tissues of healthy Balb/c mice up to 10
weeks after i.v. administration of 1.46 imol kg-' phthalo-
cyanine. The recoveries are shown in Table IV; such
recoveries are often higher (e.g. see skin and spleen) than
those found for the same tissues in tumour-bearing mice. This
Table III Recovery of ZnODPc from serum and selected tissues of
Balb/c mice bearing an intramuscularly transplanted MS-2 fibrosar-
coma, upon injection of 0.73 (dose A) and 0.37 (dose B) jumol kg-'
phthalocyanine in a Cremophor EL emulsion
Recovery (ng mg-])
3 h 24 h
Tissue Dose A Dose B Dose A Dose B
Tumour 0.9+0.04 0.4+0.1 1.5+0.2 0.9+0.3
Liver 2.9+0.5 0.7+0.2 6.9+1.4 3.0+1.3
Spleen 0.3+0.03 0.2+0.1 1.6+0.3 1.4+0.4
Kidney 0.4+0.1 0.2+0.05 0.1 +0.02 nd
Seruma 4.5+3.3 2.4+0.9 0.5+0.1 0.3+0.03
ajg ml-1; nd, not detected.
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difference has also been observed in previous experiments
(Reddi et al., 1987) and reflects the larger serum concentra-
tion of phthalocyanine in the absence of the fibrosarcoma.
Phototherapeutic studies
On the basis of the pharmacokinetic data, PDT studies with
Balb/c mice bearing an intramuscular MS-2 fibrosarcoma
were performed at 24 h after i.v. injection of 1.46 ymol kg-'
ZnODPc. As previously observed (Cook et al., 1994), the
phototreated animals exhibit a significantly slower growth of
the tumour compared with unirradiated or irradiated but
unsensitised animals. The overall effect was similar to that
obtained by previous authors (Biolo et al., 1996; Valles et al.,
1995) for other moderately vascularised tumours at
equivalent light doses. Electron microscopy analysis of
tumour specimens taken from ZnODPc-injected and un-
irradiated mice show that the phthalocyanine per se causes no
detectable alterations of the ultrastructural properties of the
fibrosarcoma.
However, in ZnODPc-photosensitised tumours, at 1 h
after the end of PDT both neoplastic cells and blood
capillaries appear to be well preserved with the exception of
some swelling of mitochondria, which is especially evident in
tumour cells (Figure 1). The photodamage becomes more
Figure 1 Tumour specimen obtained at 1 h after PDT (x 5500).
The sample differs from those obtained from control tumours by
a marked swelling of some mitochondria (m).
Table IV Recovery of ZnODPc from serum and selected tissues of healthy Balb/c mice at prolonged times
after i.v. injection of 1.46 jimol kg-' phthalocyanine in a Cremophor EL emulsion
Recovery (ng mg-')
Tissue 24 h 1 week 2 weeks 4 weeks 6 weeks 10 weeks
Liver 25.1 +2.3 28.7+2.8 32.2+2.4 28.0+2.9 26.7+2.9 20.3+ 3.8
Spleen 17.1 +1.3 19.9+4.6 15.8+2.5 10.2+3.2 16.6+2.1 14.0+2.1
Kidney 0.8+0.1 0.5+0.05 0.5+0.01 0.4+0.04 0.3+0.06 nd
Skin 3.4+0.1 nd nd 0.9+0.1 nd nd
Seruma 4.0+0.2 nd nd nd nd nd
ajig ml 1; nd, not detected.Phototherapeutic activity of ZnODPc
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evident at 3 h after PDT (Figure 2) involving most
membranous systems of malignant cells; several mitochon-
dria are swollen and optically empty, some cisternae of rough
endoplasmic reticulum are significantly altered, and the
formation of scattered vacuoles and vesicles can be
observed. At 6 h after irradiation important vascular
damage can be detected in our micrographs (Cook et al.,
1994). However, even at time intervals as long as 48 h, when
the damage to the tumour tissue becomes quite extensive, the
necrotic areas are of a somewhat focal nature and coexist
with less heavily damaged areas (Figure 3). In any case, the
photoinduced structural modifications are especially extensive
at the level of the cell membranes, whereas vacuoles occupy a
large fraction of the cytoplasmic space and the perinuclear
membrane is partially detached and discontinuous. The nuclei
appear to be markedly damaged only in massively necrotic
areas of the tumour tissue, which also show the presence of
granular material probably originating from the destruction
of neoplastic cells (Figure 4).
Interestingly, in micrographs obtained from tumour
specimens taken at short post-irradiation time intervals (1-
6 h), one can observe some unusual ultrastructural features,
including a marked vesiculation of cellular nuclei (Figures 5
and 6). No similar alterations have been found previously in
our electron microscopy analyses of different tumour models
(including the MS-2 fibrosarcoma) after PDT treatment with
a variety of phthalocyanines or other tetrapyrrolic deriva-
tives. The formation of the vesicles must be the consequence
of photochemically induced damage, since we could not
detect any analogous alteration in mice that were injected
with ZnODPc but were not exposed to light.
Lastly, as shown in Figures 7 and 8, some tumour cells
that are present in partially damaged areas exhibit
ultrastructural aspects typical of apoptotic processes: thus,
chromatin is condensed and localised at one nuclear pole,
while several blebs are formed in the swollen perinuclear
membrane; the latter also shows a few evident gaps through
which some nuclear material could move into the cytoplasm
leading to the formation of compact chromatin masses
(Figure 8). It is unlikely that the observed ultrastructural
changes reflect the occurrence of spontaneous apoptosis, since
no similar ultrastructural details could be identified in all the
twelve thin sections that were analysed from control mice.
Skin photosensitisation studies
Mice irradiated at 3 h after ZnODPc injection exhibit an
important cutaneous response: a marked skin swelling occurs
within 12 h from the end of the phototreatment and is
followed by the appearance of oedema and erythema after c.
48 h. The lesions undergo a progressive regression, although
re-epithelisation is still incomplete after I week. However, no
skin alteration can be detected in mice exposed to white light
at 15 h and 24 h after i.v. administration of ZnODPc.
These qualitative observations are fully supported by
histological examination of skin specimens taken from
control and phototreated mice. Typical pictures of unirra-
diated skin obtained using the optical microscope are shown
in Figures 9 and 10 and display the characteristic structure of
mouse skin. A closely similar organisation of the epidermal
and dermal layers is exhibited in areas of skin from
photosensitised mice that are distal to the irradiated site
(mice injected with ZnODPc 3 h before PDT treatment)
(Figure 11). However, as the analysed samples are chosen
from areas closer to the irradiated site, the indications for
photoinduced damage become more and more evident. In
particular, one can detect a loss of organisation in the deeper
districts of the dermis especially at the level of the fibrous
elements of the reticular layers; some adipocytes below the
dermis are also damaged. On the other hand, no apparent
alterations of the upper dermal areas and the epidermis can
be detected. These features are further enhanced in the
specimens corresponding to the photosensitised skin area
(Figures 12 and 13): while the epidermis and the horny layer
exhibit a normal structure, the dermis and some subcuta-
neous compartments are heavily damaged. Thus, the number
z- M~~~~~~~ ~
Figure 2 Tumour specimen obtained at 3 h after PDT (x 5500). Figure 3 Tumour specimen obtained at 24 h after PDT (x 5500).
Mitochondria (m) are significantly swollen and optically empty, The formation of numerous cytoplasmic vacuoles and a swollen
while several vesicles are formed owing to the alteration of the nuclear membrane (arrows), with relatively well-preserved nuclei,
Golgi apparatus and rough endoplasmic reticulum. can be seen.Phototherapeutic activity of ZnODPc
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Figure 4 Tumour specimen obtained at 48 h after PDT (x 5000). Figure 6 Tumour specimen obtained at 3 h after PDT (x 8500).
The organisation of the tumour tissue is almost completely lost The micrograph shows a generally well-preserved ultrastructure
and the damage involves essentially all the subcellular structures with the exception of some vesicles in the nucleus (arrows).
with evidence of karyorrhexis and disruption of the plasma
membrane.
44M ,, - DX
Figure 5 Tumour specimen obtained at I h after PDT Figure 7 Tumour specimen obtained at 6 h after PDT
( x 14 000). The micrograph shows a large vesiculation in the ( x 11 000). The nuclear membrane shows evident blebs and
cell nucleus, as well as some detachment of the perinuclear blunt protuberances with a strongly condensed chromatin.
membrane. These features have been observed in only a few cells, Moreover, the mitochondria (m) are optically empty and heavily
although such modified cells were present in many thin sections. swollen, and the rough endoplasmic reticulum (R) is extensively
No similar feature was observed in control mice. altered.Phototherapeutic activity of ZnODPc
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of the fibrous elements of the connective tissue is
substantially reduced and the overall organisation is
significantly perturbed; moreover, the adipose cells are
damaged to a great extent so that their borders are no
longer detectable.
The skin of mice phototreated at 15 h or 24 h after
injection of ZnODPc shows histological features identical
with those of control unirradiated animals.
Discussion
Our findings on the biodistribution of Cremophor-delivered
ZnODPc in Balb/c mice bearing an intramuscularly
transplanted MS-2 fibrosarcoma are in good agreement with
those obtained for other phthalocyanines in the same animal
model (Segalla et al., 1994; Soncin et al., 1995b) with regard
to the timing and amount of maximal accumulation in the
tumour (15-24 h after i.v. injection), the rate of plasma
clearance and the high concentrations recovered from liver
Figure 8 Tumour specimen obtained at 6 h after PDT
( x 30 000). The typical feature of this micrograph is the heavily
condensed chromatin at one nuclear pole, in addition to the
marked swelling and formation of gaps in the perinuclear
membrane.
Figure 10 Typical histological features of the skin obtained from
control mice. Original magnificationx 580. Abbreviations as in
Figure 9.
Figure 11 Histological features of a skin sample obtained from
Figure 9 Typical histological features of the skin obtained from PDT-treated mice at a site adjacent to the irradiated skin area.
control mice. Original magnification x 360. D, dermis; E, Slight damage is detectable in the subcutaneous adipose layer
epidermis; HB, hair bulb; SAL, subcutaneous adipose layer; SG, (x 360). D, dermis; E, epidermis; HB, hair bulb; SAL,
sebaceous glands. subcutaneous adipose layer; SG, sebaceous glands.Phototherapoutic activity of ZnODPc
C Ometto et al
Figure 12 Histological features of an irradiated skin sample
obtained from PDT-treated mice. The sample was taken at 3 h
after the end of irradiation and shows a heavily damaged
subcutaneous and dermal tissue, while the epidermis is still fairly
well preserved ( x 230). D, dermis; E, epidermis; HF, hair follicle;
SAL, subcutaneous adipose layer.
Figure 13 Same sample as shown in Figure 12. The greater
magnification yields an evident indication that the horny layer
and the underlying upper layers of the epidermis are not
appreciably altered. The dermal structure appears to be markedly
disorganised (x 580). D, dermis; E, epidermis; SG, sebaceous
glands.
and spleen. The latter property is typical of hydrophobic dyes
that are administered in association with lipid-type delivery
systems and are largely eliminated from the organism
through the bile-gut pathway (Jori, 1995). This is further
supported by the markedly lower amounts of ZnODPc
recovered from kidneys. Moreover, the negligible uptake of
this phthalocyanine in the brain is in line with the repeatedly
observed inability of porphyrin compounds to cross the
blood-brain barrier (Jori, 1995); as a consequence, one
should discard any significant risk of toxic effects of ZnODPc
at the level of the central nervous system. A comparative
analysis of the data reported in Tables III and IV suggests
that the pharmacokinetic behaviour of ZnODPc is indepen-
dent of the injected dose at least within the range 0.37-
1.46,mol kg-'
On the other hand, ZnODPc exhibits an unusually high
selectivity of tumour targeting, since no detectable amount of
phthalocyanine was found in the peritumoral tissue, i.e. the
muscle, at all monitored post-injection times and at the three
drug doses examined in the present investigation. Although
selectivity is not necessarily the most important determinant
for the efficacy and safety of PDT treatments (Henderson and
Dougherty, 1992; Ris et al., 1993), it certainly represents an
important factor in the choice of a tumour photosensitiser.
The present evidence suggests that the localisation of
porphyrin derivatives in tumours is controlled by several
different parameters (Jori, 1990; Pass, 1993; Penning and
Dubbelman, 1994). Recently, we have observed that the
selectivity and efficiency of phthalocyanine accumulation in
the MS-2 fibrosarcoma increases with an increasing degree of
hydrophobicity of the dye and the extent of phthalocyanine
associated with serum LDL (Soncin et al., 1995a). In
particular, Cremophor appears to promote a greater
selectivity of tumour targeting by a given phthalocyanine
compared with liposomal vesicles (Soncin et al., 1995b), since
it determines a larger release of the incorporated photo-
sensitiser to LDL, probably owing to a specific interaction
leading to an alteration of this component of the lipoprotein
family (Kongshaug et al., 1991; Woodburn et al., 1994). On
these bases, the extremely high selectivity of ZnODPc uptake
in the tumour can be related to its unusually high affinity for
LDL, which is clearly expressed by the data on the
distribution of this phthalocyanine among serum proteins
(see Table I). Similar conclusions were drawn from recent
investigations on the pharmacokinetic behaviour of another
highly hydrophobic photosensitising agent, namely Zn(II)-
tetradibenzobarreleno-octabutoxyphthalocyanine (Soncin et
al., 1995c).
It would be of interest to ascertain whether other factors
are responsible for modulating the accumulation and
retention of ZnODPc by neoplastic tissues, since this
information could be useful in the design of novel PDT
agents with enhanced efficacy. The mode of ZnODPc-
photosensitised tumour necrosis also shows some character-
istic features. Our electron microscopy studies clearly show
that the earliest and predominant photodamage occurs in the
membranous systems of malignant cells. This pattern of
ultrastructural changes is typical of several LDL-bound
photosensitisers (Allison et al., 1991; Zhou et al., 1988) and
represents a likely consequence of the release of ZnODPc
inside the malignant cells after receptor-mediated endocytosis
of LDL (Maziere et al., 1991). However, important vascular
damage is detected at relatively short time intervals after the
end of irradiation, which is remarkably different from that
previously observed for other hydrophobic porphyrinoids,
namely a well-preserved structure of blood capillaries for
several hours after PDT (Zhou et al., 1988, 1989). Another
peculiar feature of ZnODPc photosensitisation of tumours is
represented by the appearance of some nuclear damage even
at short post-irradiation times (see Figure 5). This
observation would suggest the need for investigations aimed
at defining whether ZnODPc-promoted photoprocesses have
any mutagenic potential, in spite of the fact that such a
possibility has never been reported for other phthalocyanines.
Our observations would suggest that ZnODPc is also
partitioned to a significant extent within endothelial cells,
since the mitochondria of such cells appears to undergo some
alterations already at 3 h after PDT.
In any case, the mechanisms by which ZnODPc exerts its
photosensitising action on tumour cells are certainly complex.
Both random cell death and apoptosis are clearly involved,
although the relative importance of the two processes cannot
be defined from our ultrastructural analyses of irradiated
samples of the MS-2 fibrosarcoma. Apparently, the occur-
rence of apoptosis is rather frequent, since unequivocal
evidence of this modality of cell death is identifiable in most
micrographs obtained from specimens of tumours taken at
1-6 h after PDT (three mice at each time, eight or nine
sections per mouse). The possibility that PDT triggers cell
apoptosis has been now recognised by several authors
(Agarwal et al., 1991; Zaidi et al., 1993; He et al., 1994)
and recently demonstrated for liposome-delivered Zn(II)-
phthalocyanine (Zhou et al., 1996). Therefore, it is not
surprising that both the above-mentioned modalities of cell
death are caused by photoactivated ZnODPc. Apoptosis
could make a major contribution to the overall photother-
apeutic process, especially in those areas where tumour
necrosis is less pronounced. This may possibly arise from an,*4 Phototherapeutic activity of ZnODPc
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inhomogeneous distribution of the phthalocyanine across the
neoplastic tissue, so that there are some compartments in
which the photosensitiser concentration is relatively small.
This may explain the high phototherapeutic activity of
ZnODPc.
One undesired side-effect induced by PDT with porphyrins
and their analogues is the persistence of cutaneous
photosensitivity for even a few weeks after systemic injection
of the dye (Dougherty, 1993). This effect has been ascribed to
a prolonged retention of the photosensitiser in the skin,
although some authors hypothesised (Zalar et al., 1977;
Henderson, 1990) a correlation between plasma levels of the
dye and skin photosensitivity. Our findings with ZnODPc
support the latter hypothesis since (1) severe photosensitised
damage to mouse skin occurs upon irradiation 3-6 h after
injection time, when only low amounts of phthalocyanine are
present in the cutaneous districts, while large levels are found
in the plasma; (2) the photosensitivity disappears as the
plasma levels of ZnODPc decrease (e.g. at 15-24 h after
injection), even if essentially the same amount of phthalo-
cyanine is now accumulated in the skin (see Table II); and (3)
histological examination of photosensitised skin shows that
the damage is largely localised in the dermis and lower
epidermis, while the upper epidermal layers are only slightly
altered.
In conclusion, a proper choice of irradiation conditions,
and particularly a suitable time interval between injection and
PDT treatment, allow one to take full advantage of the
potential of ZnODPc as a phototherapeutic agent for
tumours by combining the efficient accumulation in and
photosensitisation of the malignant lesion, the induction of
different parallel mechanisms leading to tumour necrosis, the
minimal risk of photodamaging the peritumoral tissues and
the rapid disappearance of generalised skin photosensitivity.
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